



CERTIFICATE OF ANALYSIS No.: 2022-9795

CLIENT

Pharmahemp d.o.o., Cesta v Gorice 8 1000 Ljubljana, Slovenija

SAMPLE *

CBD MIKKA EYE CONTOUR SERUM



Evnanded



| | Sample condition: | SUITABLE | Work order: | 2022-106887 | Sample received: | 08/09/2022 | |
|---------------------------------------|-------------------|----------------|--------------|----------------|--------------------|---------------|--|
| | Sample ID: | 2236027 | Analysis ID: | 2022_203 | Start of analysis: | 08/09/2022 | |
| | Sample type: | Viscous liquid | Method ID: | PHL_RPC_12C | End of analysis: | 09/09/2022 | |
| | Batch No.: * | ME00522251A | Method SOP: | MET-LAB-003-02 | Analyst: | Janez Gerdenc | |
| * Information provided by the client. | | | | | | | |

| CANNA | BINOID PROFILE | Concentration [% w/w] | Expanded uncertainty [% w/w] | Graphic presentation of relative cannabinoid concentration | |
|---|----------------------------|--------------------------|------------------------------------|--|--|
| CBDV | - Cannabidivarin | < LOQ | n/a | | |
| CBDA | - Cannabidiolic acid | < LOQ | n/a | | |
| CBGA | - Cannabigerolic acid | < LOQ | n/a | | |
| CBG | - Cannabigerol | < LOQ | n/a | | |
| CBD | - Cannabidiol | 0.495 | 0.074 | | |
| THCV | - Tetrahydrocannabivarin | < LOQ | n/a | | |
| CBN | - Cannabinol | < LOQ | n/a | | |
| Δ ⁹ -THC | - Δ-9-Tetrahydrocannabinol | < LOQ | n/a | | |
| Δ ⁸ -THC | - Δ-8-Tetrahydrocannabinol | < LOQ | n/a | | |
| CBL | - Cannabicyclol | < LOQ | n/a | | |
| CBC | - Cannabichromene | < LOQ | n/a | | |
| Δ⁹-THCA - Δ-9-Tetrahydrocannabinolic acid | | < LOQ | n/a | | |
| CBE | - Cannabielsoin | < LOQ # | n/a | | |
| CBNV | - Cannabivarin | < LOQ # | n/a | | |
| CBCA | - Cannabichromenic acid | < LOQ # | n/a | | |
| CBT | - Cannabicitran | < LOQ # | n/a | | |

 $\underline{\text{Units and abbreviations}} : \% \text{ w/w} = \text{weight percent, } < \textbf{LOQ} = \text{below the limit of quantitation (0.03 \% w/w), ND} = \text{not detected, } \textbf{n/a} = \text{not available.}$

The results given herein apply only to the sample as received. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

| Date issued: | Approved by: | Authorized by: |
|--------------------|-------------------------------|--------------------------|
| 09/09/2022 | Janya | Jany Pote |
| | mag. Ma ko Dragan | dr. Boštjan Jančar |
| | Analytical Laboratory Manager | Chief Technology Officer |
| End of Cartificate | | |